BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35139812)

  • 1. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
    Li S; Yang Y; Zou J; Zeng J; Ding C
    BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
    Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
    Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
    Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
    Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy.
    Hu L; Chen Q; Du Z; Wang W; Zhao G
    Int Ophthalmol; 2021 May; 41(5):1635-1642. PubMed ID: 33538931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Meta-Analysis of Clinical Outcomes of Small Gauge Vitrectomy with or without Intravitreal Anti-Vascular Endothelial Growth Factor Agents Pretreatment for Proliferative Diabetic Retinopathy.
    Pei M; Zhao X; Wan G
    Ophthalmic Res; 2023; 66(1):777-790. PubMed ID: 36972566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy.
    Pakzad-Vaezi K; Albiani DA; Kirker AW; Merkur AB; Kertes PJ; Eng KT; Fallah N; Forooghian F
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):521-4. PubMed ID: 25423631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
    Dervenis P; Dervenis N; Smith JM; Steel DH
    Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy.
    Xu J; Zhao M; Li JP; Liu NP
    BMC Ophthalmol; 2020 Apr; 20(1):149. PubMed ID: 32295566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study).
    Liang X; Zhang Y; Wang JX; Wang LF; Huang WR; Tang X
    Medicine (Baltimore); 2019 May; 98(20):e15735. PubMed ID: 31096535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
    Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
    Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF THE EFFICACY AND SAFETY OF RANIBIZUMAB 0.5 MG VERSUS 1.0 MG WITH PARS PLANA VITRECTOMY FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Controlled Trial.
    Su T; Lai D; Wu Y; Gu C; He S; Meng C; Cai C; Zhang J; Luo D; Chen J; Zheng Z; Qiu Q
    Retina; 2024 Apr; 44(4):680-688. PubMed ID: 38011844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and vitreous vascular endothelial growth factor levels in diabetic retinopathy.
    Sozen-Delil FI; Cekic O; Haklar G
    Int Ophthalmol; 2023 Jul; 43(7):2247-2255. PubMed ID: 36580154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conbercept and Ranibizumab Pretreatments in Vitrectomy with Silicone Oil Infusion for Severe Diabetic Retinopathy.
    Yang KB; Zhang H; Li SJ; Cao JJ; Cheng LN; Lin YX; Tian ZC; Li J; Gu F; Liu ZL
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):161-167. PubMed ID: 30668279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab.
    Hu X; Pan Q; Zheng J; Song Z; Zhang Z
    BMC Ophthalmol; 2019 Sep; 19(1):200. PubMed ID: 31519158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study).
    Comyn O; Wickham L; Charteris DG; Sullivan PM; Ezra E; Gregor Z; Aylward GW; da Cruz L; Fabinyi D; Peto T; Restori M; Xing W; Bunce C; Hykin PG; Bainbridge JW
    Eye (Lond); 2017 Sep; 31(9):1253-1258. PubMed ID: 28498374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
    Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.